Journal of Bioequivalence & Bioavailability

Stephanie McGrory B

Publications

• Research Article
  Pharmacokinetics, Pharmacodynamics, and Safety of Desvenlafaxine, a Serotonin-Norepinephrine Reuptake Inhibitor
  Author(s): Alice Nichols I, Jessica Behrle A, Virginia Parks, Lyette Richards S, Stephanie McGrory B, Joel Posener, Alain Patat and Jeffrey PaulAlice Nichols I, Jessica Behrle A, Virginia Parks, Lyette Richards S, Stephanie McGrory B, Joel Posener, Alain Patat and Jeffrey Paul
  
  Study background: Assess safety, tolerability, pharmacokinetics, and pharmacodynamics of desvenlafaxine (administered as desvenlafaxine succinate) in 3 studies with healthy volunteers. Methods: Study 1, a randomized, open-label, dose proportionality, crossover study, assessed pharmacokinetics and safety of single doses of desvenlafaxine 100, 300, and 600 mg (N=24). Study 2, a randomized, double-blind, placebo-controlled, sequential-group, single-ascending dose study, assessed pharmacokinetics, pharmacodynamics, and safety of desvenlafaxine 150–900 mg and venlafaxine extended-release 150 mg (N=79). Study 3, a doubleblind, placebo-controlled, sequential-group, multiple-ascending dose study, assessed pharmacokinetics, pharmacodynamics, and safety of desvenlafaxine 300, 450, and 600 mg (N=36). In all studies, safety was monitored through adv.. View More»
  DOI: 10.4172/jbb.1000130

  Abstract PDF